Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

    NCT02454205 · start 2015-11-12

    Registered record
    Registry ID
    NCT02454205
    Conditions
    Tuberculosis; Multidrug Resistant Tuberculosis; Extensively-drug Resistant Tuberculosis
    Interventions
    Linezolid; Bedaquiline; Levofloxacin; Pyrazinamide; Isoniazid; Ethionamide; Terizidone; Moxifloxacin; Kanamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-11-12
    Completion
    2021-08-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Tuberculosis; Extensively-drug Resistant Tuberculosis
    InterventionLinezolid; Bedaquiline; Levofloxacin; Pyrazinamide +5 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers

    NCT02602509 · start 2015-11

    Registered record
    Registry ID
    NCT02602509
    Conditions
    Tuberculosis
    Interventions
    Celecoxib; Rifampicin; Pyrazinamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-11
    Completion
    2016-02
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionCelecoxib; Rifampicin; Pyrazinamide
    PhasePhase 1
    Registry statusCompleted

  • IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

    NCT02383849 · start 2015-08-04

    Registered record
    Registry ID
    NCT02383849
    Conditions
    Low-Birth-Weight Infant; Tuberculosis; HIV
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-08-04
    Completion
    2020-02-14
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow-Birth-Weight Infant; Tuberculosis; HIV
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Assessing PA-824 for Tuberculosis (the APT Trial)

    NCT02256696 · start 2015-04-29

    Registered record
    Registry ID
    NCT02256696
    Conditions
    Pulmonary Tuberculosis
    Interventions
    PA-824; Rifampin; Rifabutin; Pyrazinamide; Ethambutol; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-04-29
    Completion
    2022-05-01
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionPA-824; Rifampin; Rifabutin; Pyrazinamide +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB

    NCT02333799 · start 2015-03

    Registered record
    Registry ID
    NCT02333799
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Bedaquiline; PA-824; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-03
    Completion
    2020-08-03
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBedaquiline; PA-824; Linezolid
    PhasePhase 3
    Registry statusCompleted

  • An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

    NCT02365623 · start 2015-02-18

    Registered record
    Registry ID
    NCT02365623
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    TMC207 (bedaquiline); Background Regimen (BR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02-18
    Completion
    2018-11-08
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionTMC207 (bedaquiline); Background Regimen (BR)
    PhasePhase 2
    Registry statusCompleted

  • Shortening Treatment by Advancing Novel Drugs

    NCT02342886 · start 2015-02

    Registered record
    Registry ID
    NCT02342886
    Conditions
    Tuberculosis, Pulmonary, Drug Sensitive; Tuberculosis, Pulmonary, Multi Drug-resistant
    Interventions
    Moxifloxacin; PA-824; Pyrazinamide; HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination); HR (rifampicin plus isoniazid combination tablets)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02
    Completion
    2018-05
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary, Drug Sensitive; Tuberculosis, Pulmonary, Multi Drug-resistant
    InterventionMoxifloxacin; PA-824; Pyrazinamide; HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) +1 more
    PhasePhase 3
    Registry statusCompleted

  • Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers

    NCT02387242 · start 2015-02

    Registered record
    Registry ID
    NCT02387242
    Conditions
    Tuberculosis
    Interventions
    Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Suspended
    Start
    2015-02
    Completion
    2017-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifampicin
    PhasePhase 1
    Registry statusSuspended

  • Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

    NCT02393586 · start 2015-02

    Registered record
    Registry ID
    NCT02393586
    Conditions
    Tuberculosis
    Interventions
    Faropenem; Amoxicillin/clavulanic acid 500mg/125mg; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-10
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionFaropenem; Amoxicillin/clavulanic acid 500mg/125mg; Rifampicin
    PhasePhase 1
    Registry statusCompleted

  • A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

    NCT02193776 · start 2014-10-23

    Registered record
    Registry ID
    NCT02193776
    Conditions
    Tuberculosis
    Interventions
    PA-824; bedaquiline; moxifloxacin; pyrazinamide; isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-10-23
    Completion
    2018-02-07
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPA-824; bedaquiline; moxifloxacin; pyrazinamide +1 more
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis

    NCT02349841 · start 2014-09

    Registered record
    Registry ID
    NCT02349841
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Meropenem; Faropenem; Amoxycillin/clavulanic acid; Rifafour e275
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09
    Completion
    2014-12
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionMeropenem; Faropenem; Amoxycillin/clavulanic acid; Rifafour e275
    PhasePhase 2
    Registry statusCompleted

  • Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan

    NCT02208427 · start 2014-08

    Registered record
    Registry ID
    NCT02208427
    Conditions
    Latent Tuberculosis Infection
    Interventions
    Rifapentine and Isoniazid for 3 months; Isoniazid for 9 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-08
    Completion
    2016-12
    Enrolment
    283

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis Infection
    InterventionRifapentine and Isoniazid for 3 months; Isoniazid for 9 months
    PhasePhase 3
    Registry statusUnknown

  • Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis

    NCT02464683 · start 2014-04

    Registered record
    Registry ID
    NCT02464683
    Conditions
    Pulmonary Tuberculosis
    Interventions
    VitaminD
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-04
    Completion
    2016-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionVitaminD
    PhasePhase 4
    Registry statusUnknown

  • 68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT

    NCT02481726 · start 2014-03

    Registered record
    Registry ID
    NCT02481726
    Conditions
    Lung Cancer; Lung Tuberculosis
    Interventions
    68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    Not recorded
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Lung Tuberculosis
    Intervention68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents

    NCT03230409 · start 2014-01-01

    Registered record
    Registry ID
    NCT03230409
    Conditions
    Tuberculosis
    Interventions
    Leaflet written in the patient's/family mother tongue; A follow-up telephone call; Eidus-Hamilton Test; A written questionnaire
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-01-01
    Completion
    2017-01-15
    Enrolment
    359

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionLeaflet written in the patient's/family mother tongue; A follow-up telephone call; Eidus-Hamilton Test; A written questionnaire
    PhaseNot applicable
    Registry statusCompleted